Home/Pipeline/LMP744

LMP744

Glioblastoma

Phase 2Active

Key Facts

Indication

Glioblastoma

Phase

Phase 2

Status

Active

Company

Gibson Oncology

About Gibson Oncology

Gibson Oncology is a private, pre-revenue biotech founded in 2018, headquartered in Nashville, TN, with a significant operational presence in Miami, FL. Its lead asset, LMP744, has received FDA Orphan Drug Designation for glioblastoma and is entering a Phase II trial in collaboration with the NIH, leveraging its unique dual Top1/cMYC inhibition and ability to cross the blood-brain barrier. The company's broader pipeline includes additional licensed compounds (LMP400, LMP776) and an internally discovered oral class of Aza Indenoisoquinolines, targeting homologous recombination deficient cancers and offering potential synergy with PARP inhibitors.

View full company profile

Therapeutic Areas

Oncology Glioblastoma Brain Cancer

Other Glioblastoma Drugs

Drug	Company	Phase	Status
Ropidoxuridine (IPdR)	Shuttle Pharmaceuticals	Phase 2	Active
LNTH-2505	Lantheus Medical Imaging	Preclinical	Active
Leronlimab	CytoDyn	Preclinical	Phase in progress
Glioblastoma Moonshot	Owkin	Research	Open Project
OPC-001 (PDC Candidate)	Oncopeptides	Phase 1/Window-of-Opportunity	Active (Fast-Track Designation)
αvβ3-targeted ADC	Xintela	Preclinical	Lead Optimization
Undisclosed	Biossil	Phase 2/3	Active
GLIX1	Hemispherian	Phase 1	Active
InC01	InCephalo Therapeutics	Pre-clinical	Active
Glioblastoma Combination Therapy	JLP Health	Pre-clinical	Active
ENV105	Kairos Pharma	IND Cleared	Active
BEA-17	Beactica Therapeutics	Pre-clinical	Active